What is 23andMe's stock forecast?

23andMe (ME) stock soared 21 percent on its public market debut. Its SPAC merger with VG Acquisition (VGAC) gave the genetic testing company an enterprise value of $3.5 billion. What is 23andMe's stock forecast, and how high can it go?

Is 23andMe (vgac) a good stock to buy?

VGAC stock has traded at between $9.65 and $18.16 since its debut. It’s currently 6 percent above its low and 44 percent below its peak. As Wall Street hasn’t started covering the stock, analysts haven't yet given it a price target. However, 23andMe's stock forecast looks bullish. 23andMe is a well-funded business.

Is 23andMe a good buy now?

Is the stock a good buy now? Founded in 2006, 23andMe is a genetics company best known for its in-home DNA testing kits. After the transaction closes, VGAC investors and sponsors will own 13 percent of 23andMe, while PIPE (private investment in public equity) investors will own 6 percent.

What is the upside for 23andMe (23andMe)?

According to analysts' consensus price target of $5.60, 23andMe has a forecasted upside of 145.6% from its current price of $2.28. 23andMe has received no research coverage in the past 90 days. 23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics.